Lynk 003 : A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Bowel<br/>CancersCancer LocationBowel
Cancers

Systemic therapy,Treatment | Bowel (colorectum)Colorectum

Trial Overview Read MoreRead more

This phase III trial is trying to evaluate the safety and effectiveness of a targeted cancer drug, given alone and in combination with another targeted cancer drug or chemotherapy, for the treatment of patients with a colorectal cancer that has spread to other parts of the body.
 

This trial is treating patients with colorectal (bowel) cancer.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Commercial Sponsor

Merck

Summary

Eligible patients will be randomised into one of three arms of the study. In the first arm, patients will receive oral Olaparib twice daily and intravenous Bevacizumab once every two weeks, until progressive disease or end of the study. In the second arm, patients will receive oral Olaparib alone, twice daily, until progressive disease or end of the study. In the third arm, the active comparator arm, patients will receive intravenous Bevacizumab every two weeks and 5-FU chemotherapy every two weeks, until progressive disease or end of study.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
GI Research Study Coordinator
gi.oncresearch@monashhealth.org
0436386758

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next